Treating two active malignancies concurrently can be exceedingly difficult. Complications can occur from the different treatment regimens, especially if they share common targets, and the progressing diseases can make managing treatment side-effects even more challenging. We report a case of a patient with coexisting CML and mRCC who progressed on multiple lines of mRCC therapy while experiencing significant dose limiting side-effects.
FacchiniGPerriFCaragliaM. New treatment approaches in renal cell carcinoma. Anticancer Drugs2009; 20: 893–900.
5.
MotzerRJHutsonTETomczakP. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol2009; 27: 3584–3590.
6.
Garcia-ManeroGFaderlSO’BrienS. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer2003; 98: 437–457.
7.
O’BrienSGGuilhotFLarsonRA. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med2003; 348: 994–1004.
8.
DrukerBJGuilhotFO’BrienSG. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med2006; 355: 2408–2414.
9.
CortesJBorthakurGO'BrienS. Efficacy of dasatinib in patients with previously untreated chronic myelogenous leukemia in early chronic phase. Blood2009; 114: 143–143. (abstract 338).
10.
CortesJJonesDO’BrienS. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol2010; 28: 392–397.
HainsworthJDSpigelDRSosmanJA. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin Genitourin Cancer2007; 5: 427–432.
17.
PalSKGuptaRKDosikGFiglinRA.Concomitant renal cell carcinoma and chronic myelogenous leukemia: use of a targeted approach. Curr Oncol2009; 16: 44–47.
MotzerRJEscudierBOudardS. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet2008; 372: 449–456.
20.
EllardSLClemonsMGelmonKA.Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol2009; 27: 4536–4541.
